Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Debra Hanks
Clinical Utility of the Combined Positive Score for Programmed Death Ligand-1 Expression and the Approval of Pembrolizumab for Treatment of Gastric Cancer
Archives of Pathology and Laboratory Medicine
Medicine
Forensic Medicine
Pathology
Medical Laboratory Technology
Related publications
Complete and Sustained Response of Brain Metastases to Programmed Death 1 Antibody Monotherapy in Treatment-Naive Programmed Death Ligand 1–Positive Lung Cancer
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Expression of Programmed Cell Death-Ligand 1 and Its Correlation With Clinical Outcomes in Gliomas
Oncotarget
Oncology
Clinicopathological Significance and Prognostic Implication of Programmed Death-1 Ligand 2 Expression in Colorectal Cancer
International Journal of Biological Markers
Oncology
Cancer Research
Clinical Biochemistry
Forensic Medicine
Medicine
Pathology
Topotecan Decreases the Expression of Programmed Death-Ligand 1 in Glioblastoma Cell Lines; Implications for Immunotherapy
Matters
Pembrolizumab as First-Line Therapy in Programmed Death Ligand 1-Positive Advanced Lung Cancer: Is It as Effective as We Think It Is?
Cancer
Cancer Research
Oncology
Programmed Death-Ligand 1 Expression and Its Correlation With Clinicopathological Parameters in Gallbladder Cancer
Journal of Pathology and Translational Medicine
Forensic Medicine
Pathology
Histology
Clinicopathologic Significance and Immunogenomic Analysis of Programmed Death-Ligand 1 (PD-L1) and Programmed Death 1 (PD-1) Expression in Thymic Epithelial Tumors
Frontiers in Oncology
Cancer Research
Oncology
MicroRNAs Aid the Assessment of Programmed Death Ligand�1 Expression in Patients With Non‑small Cell Lung Cancer
Oncology Letters
Cancer Research
Oncology
Programmed Death Ligand 1 (PD-L1) Expression in Primary Angiosarcoma
Journal of Cancer
Oncology
